Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber

Thrombosis Research

Volumn 132, Issue 2, 2013, Pages 240-247

  Wolzt, Michael ^a   Gouya, Ghazaleh ^a   Kapiotis, Stylianos ^a   Becka, Michael ^b   Mueck, Wolfgang ^b   Kubitza, Dagmar ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BAYER PHARMA AG   (Germany)

Author keywords

Acetylsalicylic acid; Arterial thrombosis; Rivaroxaban; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; D DIMER; RIVAROXABAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; AORTA STRIP; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SAFETY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NONHUMAN; NORMAL HUMAN; OPEN STUDY; PERFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHEAR RATE; SWINE; THROMBUS;

ACETYLSALICYLIC ACID; ACS; ACTIVATED PARTIAL THROMBOPLASTIN TIME; ACUTE CORONARY SYNDROME; ANALYSIS OF COVARIANCE; ANCOVA; APTT; ARTERIAL THROMBOSIS; ASA; C(MAX); C(TROUGH); CI; COEFFICIENT OF VARIATION; CONFIDENCE INTERVAL; CV; ENDOGENOUS THROMBIN POTENTIAL; ETP; LD; LEAST SQUARES; LOADING DOSE; LS; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; OD; ONCE DAILY; PROTHROMBIN TIME; PT; RIVAROXABAN; SD; STANDARD DEVIATION; VENOUS THROMBOSIS; VITAMIN K ANTAGONIST; VKA;

ADOLESCENT; ADULT; ANIMALS; ANTICOAGULANTS; ASPIRIN; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PLATELET AGGREGATION; SWINE; THIOPHENES; THROMBOSIS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84883817592     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.05.019     Document Type: Article

References (39)

1. J.L. Anderson, C.D. Adams, E.M. Antman, C.R. Bridges, R.M. Califf, and D.E. Casey Jr. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 123 2011 e426 e579
2. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, and H. Bueno ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-segment Elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
3. N. Mackman Triggers, targets and treatments for thrombosis Nature 451 2008 914 918
4. A.G.G. Turpie, and C. Esmon Venous and arterial thrombosis - pathogenesis and the rationale for anticoagulation Thromb Haemost 105 2011 586 596
5. F. Andreotti, L. Testa, G.G. Biondi-Zoccai, and F. Crea Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Eur Heart J 27 2006 519 526
6. M.B. Rothberg, C. Celestin, L.D. Fiore, E. Lawler, and J.R. Cook Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit Ann Intern Med 143 2005 241 250
7. H.J. Zhao, Z.T. Zheng, Z.H. Wang, S.H. Li, Y. Zhang, and M. Zhong "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment Chest 139 2011 260 270
8. J.W. Eikelboom, and J.I. Weitz New anticoagulants Circulation 121 2010 1523 1532
9. F. Depasse, J. Busson, J. Mnich, L. Le Flem, G.T. Gerotziafas, and M.M. Samama Effect of BAY 59-7939 - a novel, oral, direct Factor Xa inhibitor - on clot-bound Factor Xa activity in vitro J Thromb Haemost 3 Suppl. 1 2005 P1104
10. E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig, and K.H. Schlemmer In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor J Thromb Haemost 3 2005 514 521
11. E. Perzborn, and U. Lange Rivaroxaban - an oral, direct Factor Xa inhibitor - inhibits tissue factor-mediated platelet aggregation J Thromb Haemost 5 Suppl. 2 2007 [P-W-642]
12. E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, and F. Misselwitz The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor Nat Rev Drug Discov 10 2011 61 75
13. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775
14. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, and J. Muntz Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 31 39
15. M.R. Lassen, W. Ageno, L.C. Borris, J.R. Lieberman, N. Rosencher, and T.J. Bandel Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786
16. A.G.G. Turpie, M.R. Lassen, B.L. Davidson, K.A. Bauer, M. Gent, and L.M. Kwong Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 2009 1673 1680
17. The EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
18. The EINSTEIN-PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
19. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
20. J.L. Mega, E. Braunwald, S.D. Wiviott, J.P. Bassand, D.L. Bhatt, and C. Bode Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
21. H.R. Baumgartner The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi Microvasc Res 5 1973 167 179
22. M. Wolzt, U.G. Eriksson, G. Gouya, N. Leuchten, S. Kapiotis, and M. Elg Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists Thromb Res 129 2012 e83 e91
23. L. Badimon, V. Turitto, J.A. Rosemark, J.J. Badimon, and V. Fuster Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene J Lab Clin Med 110 1987 706 718
24. A.K. Kurklinsky, H. Kalsi, W.E. Wysokinski, K.F. Mauck, A. Bhagra, and R.D. Havyer Fibrin D-dimer concentration, deep vein thrombosis symptom duration, and venous thrombus volume Angiology 62 2011 253 256
25. I. Pabinger, and C. Ay Biomarkers and venous thromboembolism Arterioscler Thromb Vasc Biol 29 2009 332 336
26. M.U. Zafar, D.A. Vorchheimer, J. Gaztanaga, M. Velez, D. Yadegar, and P.R. Moreno Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber Thromb Haemost 98 2007 883 888
27. D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, and G. Wensing Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor Clin Pharmacol Ther 78 2005 412 421
28. G. Rohde Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 872 2008 43 50
29. G.T. Gerotziafas, I. Elalamy, F. Depasse, E. Perzborn, and M.M. Samama In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct Factor Xa inhibitor rivaroxaban J Thromb Haemost 5 2007 886 888
30. D. Kubitza, M. Becka, G. Wensing, B. Voith, and M. Zuehlsdorf Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects Eur J Clin Pharmacol 61 2005 873 880
31. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - are not affected by aspirin J Clin Pharmacol 46 2006 981 990
32. E. Perzborn, E. Fischer, and U. Lange Combining rivaroxaban with acetylsalicylic acid increases antithrombotic potency without affecting bleeding times in animal models J Thromb Haemost 5 Suppl. 2 2007 [P-W-639]
33. E. Perzborn, E. Fischer, and U. Lange Rivaroxaban, a novel, oral, direct Factor Xa inhibitor, enhanced the effects of clopidogrel and acetylsalicylic acid in rats Eur Heart J 28 Suppl. 1 2007 189
34. E. Perzborn, S. Heitmeier, and V. Laux Concomitant administration of antiplatelet agents enhances the antithrombotic effects of rivaroxaban in vitro and in vivo Eur Heart J 304 2012 [A1835]
35. D. Shimbo, J. Osende, J. Chen, J. Robbins, Y. Shimoto, and S. Kunitada Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin Thromb Haemost 88 2002 733 738
36. U. Orvim, R.M. Barstad, H. Stormorken, F. Brosstad, and K.S. Sakariassen Immunologic quantification of fibrin deposition in thrombi formed in flowing native human blood Br J Haematol 95 1996 389 398
37. C.M. Gibson, J.L. Mega, P. Burton, S. Goto, F. Verheugt, and C. Bode Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome Am Heart J 161 2011 815 821
38. J.H. Alexander, R.D. Lopes, S. James, R. Kilaru, Y. He, and P. Mohan Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
39. J. Oldgren, A. Budaj, C.B. Granger, Y. Khder, J. Roberts, and A. Siegbahn Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2011 2781 2789